Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03410875
Title A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Yale University New Haven Connecticut 06511 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
Memorial Sloan Kettering at Basking Ridge Basking Ridge New Jersey 07920 United States Details
Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey 07748 United States Details
Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey 07645 United States Details
Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities) Commack New York 11725 United States Details
Memorial Sloan Kettering Westchester (Limited Protocol Activities) Harrison New York 10604 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10021 United States Details
Memorial Sloan Kettering Nassau (Limited Protocol Activities) Uniondale New York 11553 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field